ArticleBMC medicine2018

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?

Alessandro MorabitoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.